ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder

ProQR Therapeutics N.V.  shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10).